Evidence map›Paper›PMID 36967224›Full record

SynthesisChronic respiratory disease

The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis.

Kazuya Tanimura, Susumu Sato, Yukio Fujita, Yoshifumi Yamamoto, Takashi Hajiro, Nobuyuki Horita, Tomotaka Kawayama, Shigeo Muro

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Chronic respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Kazuya TanimuraDepartment of Respiratory Medicine, 12967Nara Medical University, Kashihara, Japan.ORCID 0000-0002-3406-9394
Susumu SatoDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-9626-1090
Yukio FujitaDepartment of Respiratory Medicine, 12967Nara Medical University, Kashihara, Japan.
Yoshifumi YamamotoDepartment of Respiratory Medicine, 12967Nara Medical University, Kashihara, Japan.
Takashi HajiroDepartment of Respiratory Medicine, 13802Tenri Hospital, Tenri, Japan.
Nobuyuki HoritaDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Tomotaka KawayamaDivision of Respirology, Neurology, and Rheumatology, Department of Medicine, 26333Kurume University School of Medicine, Kurume, Japan.
Shigeo MuroDepartment of Respiratory Medicine, 12967Nara Medical University, Kashihara, Japan.ORCID 0000-0001-7452-9191
Nara Medical University · JPKyoto University · JPKurume University · JPTenri Hospital · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe rationale for additional treatment with short-acting bronchodilators combined with long-acting bronchodilators for patients with chronic obstructive pulmonary disease (COPD) is not adequately studied.

methodsWe conducted a systematic review and meta-analysis to evaluate the efficacy and safety of a short-acting muscarinic antagonist (SAMA) therapy combined with a long-acting beta-2 agonist (LABA) in patients with stable COPD. Pulmonary function, dyspnea, health-related quality of life, exercise tolerance, physical activity, exacerbations of COPD, and adverse events during regular use were set as outcomes of interest.

resultsWe included five controlled trials including two sets of publicly available online data without article publications for the meta-analysis. Additional use of SAMA plus LABA showed a significant improvement in the peak response in FEV

conclusionAdditional treatment with SAMA combined with LABA could be a feasible choice due to its efficacy and safety.

Indexed as

Muscarinic AntagonistsPulmonary Disease, Chronic ObstructiveAdministration, InhalationAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsDyspneaHumansQuality of LifeAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsMuscarinic Antagonistschronic obstructive pulmonary diseaseefficacylong-acting beta2-agonistsafetyshort-acting bronchodilatorsShort-acting muscarinic antagonist

Identifiers

PMID36967224
PMCPMC10052583
OpenAlexW4360998174

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.